Herpes Zoster Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Herpes Zoster pipeline constitutes 18+ key companies continuously working towards developing 20+ Herpes Zoster treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Herpes Zoster Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Herpes Zoster Market.

The Herpes Zoster Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Herpes Zoster Pipeline Report: https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Herpes Zoster treatment therapies with a considerable amount of success over the years.
• Herpes Zoster companies working in the treatment market are CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc, Changchun BCHT Biotechnology, and others, are developing therapies for the Herpes Zoster treatment
• Emerging Herpes Zoster therapies in the different phases of clinical trials are- VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others are expected to have a significant impact on the Herpes Zoster market in the coming years.
• In February 2025, CSPC Pharmaceutical Group Ltd. has received approval from China's National Medical Products Administration (NMPA) to begin clinical trials for SYS-6017, an mRNA-based vaccine developed to prevent herpes zoster infections.
• In September 2024, GSK announced that Part II of the Phase I/II TH HSV REC-003 trial evaluating its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not achieve its primary efficacy endpoint. The findings were based on an analysis of primary objective data from the Phase II portion of the study. Despite its goal of offering a new therapeutic option for HSV, the trial results led GSK to discontinue plans for advancing the vaccine to Phase III studies.
• In June 2024, Dynavax Technologies administered the first dose in a Phase I/II clinical trial evaluating Z-1018, an investigational shingles (herpes zoster) vaccine. This randomized, active-controlled, dose-escalation, multi-center study is expected to enroll approximately 440 healthy adults aged 50 to 69 across multiple Australian sites
• In January 2024, Jiangsu Recbio Technology, headquartered in China, has reported encouraging findings from its initial human trial of a shingles vaccine. This trial assessed REC610, an innovative adjuvanted recombinant shingles vaccine, in comparison to GSK's Shingrix. REC610 aims to stimulate the generation of significant quantities of VZV glycoprotein E (gE)-specific CD4+ T cells and antibodies, with the goal of preventing shingles among individuals aged 40 and older.

Herpes Zoster Overview
Herpes Zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus-the same virus that causes chickenpox. It typically presents as a painful, blistering skin rash that appears on one side of the body, often in a stripe-like pattern. Other symptoms may include burning, itching, or tingling sensations before the rash develops. Herpes zoster is more common in older adults or individuals with weakened immune systems. Complications can include postherpetic neuralgia, a condition causing long-lasting nerve pain. Antiviral medications can help reduce the severity and duration of the infection if treated early.

Get a Free Sample PDF Report to know more about Herpes Zoster Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Herpes Zoster Drugs Under Different Phases of Clinical Development Include:
• VZV Vaccine: CPL Biologics
• Herpes Zoster vaccine: EuBiologics
• mRNA-1468 Moderna
• GLS5100: Gene One Life Science
• Z-1018 Dynavax Technologies Corporation
• EG-HZ: EyeGene
• CRV101: Curevo Inc
• Varicella zoster virus vaccine: Changchun BCHT Biotechnology

Herpes Zoster Route of Administration
Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Herpes Zoster Molecule Type
Herpes Zoster Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Herpes Zoster Pipeline Therapeutics Assessment
• Herpes Zoster Assessment by Product Type
• Herpes Zoster By Stage and Product Type
• Herpes Zoster Assessment by Route of Administration
• Herpes Zoster By Stage and Route of Administration
• Herpes Zoster Assessment by Molecule Type
• Herpes Zoster by Stage and Molecule Type

DelveInsight's Herpes Zoster Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Herpes Zoster product details are provided in the report. Download the Herpes Zoster pipeline report to learn more about the emerging Herpes Zoster therapies
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Herpes Zoster Therapeutics Market include:
Key companies developing therapies for Herpes Zoster are - Viatris Inc., Takeda Pharmaceutical Company Limited, Novartis AG, GlaxoSmithKline PLC, Merck & Co. Inc., Apotex Inc., Pfizer Inc., Hetero Drug (Camber Pharmaceuticals, Inc.), Cipla Inc., and others.

Herpes Zoster Pipeline Analysis:
The Herpes Zoster pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Herpes Zoster with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Herpes Zoster Treatment.
• Herpes Zoster key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Herpes Zoster Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Herpes Zoster market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Herpes Zoster drugs and therapies
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Herpes Zoster Pipeline Market Drivers
• Increasing awareness and high demand for shingles prevention, rising incidence of herpes zoster, increasing awareness and high demand for shingles prevention, favorable reimbursement and funding policies are some of the important factors that are fueling the Herpes Zoster Market.

Herpes Zoster Pipeline Market Barriers
• However, high cost of vaccines, lack of vaccine compliance and knowledge about Shingles prevention, logistical and storage barriers, side effects associated with the current treatment options and other factors are creating obstacles in the Herpes Zoster Market growth.

Scope of Herpes Zoster Pipeline Drug Insight
• Coverage: Global
• Key Herpes Zoster Companies: CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc, Changchun BCHT Biotechnology, and others
• Key Herpes Zoster Therapies: VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others
• Herpes Zoster Therapeutic Assessment: Herpes Zoster current marketed and Herpes Zoster emerging therapies
• Herpes Zoster Market Dynamics: Herpes Zoster market drivers and Herpes Zoster market barriers

Request for Sample PDF Report for Herpes Zoster Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Herpes Zoster Report Introduction
2. Herpes Zoster Executive Summary
3. Herpes Zoster Overview
4. Herpes Zoster- Analytical Perspective In-depth Commercial Assessment
5. Herpes Zoster Pipeline Therapeutics
6. Herpes Zoster Late Stage Products (Phase II/III)
7. Herpes Zoster Mid Stage Products (Phase II)
8. Herpes Zoster Early Stage Products (Phase I)
9. Herpes Zoster Preclinical Stage Products
10. Herpes Zoster Therapeutics Assessment
11. Herpes Zoster Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Herpes Zoster Key Companies
14. Herpes Zoster Key Products
15. Herpes Zoster Unmet Needs
16 . Herpes Zoster Market Drivers and Barriers
17. Herpes Zoster Future Perspectives and Conclusion
18. Herpes Zoster Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Herpes Zoster Market https://www.delveinsight.com/report-store/herpes-zoster-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Herpes Zoster Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Herpes Zoster Epidemiology https://www.delveinsight.com/report-store/herpes-zoster-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Herpes Zoster Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Interspinous Spacers Market: https://www.delveinsight.com/report-store/interspinous-spacers-market
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.